NAMS(NAMS)
NAMS
ANALYST COVERAGE10 analysts
BUY
▲ +27.4%upside to target
L $37.00
Med $46.00consensus
H $55.00Key MetricsTTM
Market Cap$4.18B
Revenue TTM$22.57M
Net Income TTM-$212.73M
Free Cash Flow-$142.19M
Gross Margin97.5%
Operating Margin-953.6%
Net Margin-942.8%
Return on Equity-29.8%
Return on Assets-29.0%
Debt / Equity0.00
Current Ratio9.76
EPS TTM$-1.76
PRICE
Prev Close
35.75
Open
35.06
Day Range35.00 – 36.47
35.00
36.47
52W Range16.79 – 42.21
16.79
42.21
76% of range
VOLUME & SIZE
Avg Volume
1.1M
FUNDAMENTALS
P/E Ratio
-20.3x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
45
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PDividend Pay
In 97 days
Aug 26
NAMS News
About
No description available.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Johannes Jacob Pieter Kastelein FESCFounder, Chief Scientific Officer, Member of Executive Board & Director
Marc DitmarschChief Development Officer
Michael Harvey Davidson FACC Facp.CEO, President & Executive Director
Bob RamboExecutive Vice President of Marketing
Douglas F. KlingChief Operating Officer
Matthew PhilippeExecutive Vice President &Head of Investor Relations
Mayur Amrat SomaiyaChief Financial Officer
Juliette AudetChief Strategy & Business Officer
Louise KooijChief Accounting Officer
Maryellen McQuadeChief People Officer